Paraganglioma of the head and neck region, treated with radiation therapy, a Rare Cancer Network study.


Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
06 2019
Historique:
received: 02 07 2018
revised: 29 10 2018
accepted: 10 12 2018
pubmed: 12 1 2019
medline: 11 11 2020
entrez: 12 1 2019
Statut: ppublish

Résumé

Paraganglioma of the head and neck (HNPGL) are rare often benign tumors. Surgery and radiation therapy (RT) are the main treatment choices. We present an analysis of outcome and toxicity after RT from 13 institutions of the Rare Cancer Network. Data were collected using a questionnaire concerning patients' characteristics, treatment, and outcome. A total of 81 patients with 82 HNPGL were analyzed. The median follow-up was 48 months (1-456). Sixty-two lesions were treated with conventional RT and 20 lesions with stereotactic RT. Local control (LC) was achieved in 69 out of 77 lesions. Late toxicity occurred in 17 patients. Patients treated with stereotactic RT experienced neither disease progression nor late toxicity. Four patients with a follow-up longer than 20 years experienced disease progression. RT for HNPGL offered good local control with acceptable toxicity. Stereotactic RT might offer better results. Long-term follow-up is required.

Sections du résumé

BACKGROUND
Paraganglioma of the head and neck (HNPGL) are rare often benign tumors. Surgery and radiation therapy (RT) are the main treatment choices. We present an analysis of outcome and toxicity after RT from 13 institutions of the Rare Cancer Network.
METHODS
Data were collected using a questionnaire concerning patients' characteristics, treatment, and outcome. A total of 81 patients with 82 HNPGL were analyzed.
RESULTS
The median follow-up was 48 months (1-456). Sixty-two lesions were treated with conventional RT and 20 lesions with stereotactic RT. Local control (LC) was achieved in 69 out of 77 lesions. Late toxicity occurred in 17 patients. Patients treated with stereotactic RT experienced neither disease progression nor late toxicity. Four patients with a follow-up longer than 20 years experienced disease progression.
CONCLUSION
RT for HNPGL offered good local control with acceptable toxicity. Stereotactic RT might offer better results. Long-term follow-up is required.

Identifiants

pubmed: 30633446
doi: 10.1002/hed.25611
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1770-1776

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Yasmin Lassen-Ramshad (Y)

Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Enis Ozyar (E)

Acibadem M.A. Aydinlar University, School of Medicine, Department of Radiation Oncology, Turkey.

Senem Alanyali (S)

Department of Radiation Oncology, Ege University Faculty of Medicine, Turkey.

Philip Poortmans (P)

Department of Radiation Oncology, Institut Curie, Paris, France.

Paul van Houtte (P)

Department of Radiation Oncology, Jules Bordet Institute, Brussels, Belgium.

Schoeb Sohawon (S)

Department of Radiation Oncology, Jules Bordet Institute, Brussels, Belgium.

Mustafa Esassolak (M)

Department of Radiation Oncology, Ege University Faculty of Medicine, Turkey.

Marco Krengli (M)

Department of Radiotherapy, University of Piemonte Orientale Novara, Italy.

Salvador Villa (S)

Department of Radiation Oncology, Catalan Institute of Oncoloy, Badalona, Spain.

Robert Miller (R)

Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.

Candan Demiroz (C)

Uludag University Faculty of Medicine, Radiation Oncology Clinical Division, Turkey.

Serap Akyurek (S)

Department of Radiotherapy, Ankara University School of Medicine, Turkey.

Ninna Aggerholm-Pedersen (N)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Juliette Thariat (J)

Radiation Oncology Department, Centre Francois Baclesse, Caen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH